Introduction
============

Electroconvulsive therapy (ECT) remains the gold-standard treatment for severe, treatment-resistant patients with major depressive disorder (MDD) where a rapid response is indicated. The ECT success rate in MDD, the most common diagnostic indication for the estimated 100,000 annual ECT treatments in the U.S., is approximately 75% (Hermann et al., [@B23]; Weiner et al., [@B49]). During a 3--4 week course of an ECT series, most depressive episodes remit, and formerly suicidal or psychotically depressed patients will resume their premorbid levels of functioning. The short time interval and magnitude of response make ECT an ideal therapeutic intervention to assess biomarkers of response in MDD. Resting state functional magnetic resonance imaging (fMRI) has recently expanded the scope and generalizability of fMRI investigations to include patients with severe MDD treated with ECT (Beall et al., [@B4]; Perrin et al., [@B38]).

Functional connectivity in resting fMRI data has become a widely used technique and can be measured in various ways (Erhardt et al., [@B11]). The two most widely used approaches include the use of a seed-based method (Biswal et al., [@B5]) and spatial independent component analysis (ICA; McKeown et al., [@B36]; Calhoun and Adali, [@B6]). A cross-sectional seed-based approach of MDD revealed increased temporal coherence within limbic, cortical, and default mode networks (Sheline et al., [@B46]). Furthermore, these networks overlapped with an area of the dorsal medial prefrontal cortex (DMPFC). The increased temporal coherence of these brain regions may be an important therapeutic target in MDD. Perrin et al. ([@B38]) tested this hypothesis with a longitudinal resting state fMRI investigation and found that ECT response was associated with reduced temporal coherence within the left dorsal lateral prefrontal cortex (l_DLPFC; Perrin et al., [@B38]).

In contrast to the seed-based approach, spatial ICA utilizes a data-driven multivariate approach to identify distinct groups of brain regions with temporally coherent (and hence functionally connected) hemodynamic signal change (Calhoun et al., [@B8]). While the ICA spatial maps are maximally independent, their respective time courses can have considerable temporal dependencies. Functional network connectivity (FNC) measures correlations between component time courses (Jafri et al., [@B24]). FNC has been applied to fMRI investigations of schizophrenia, aging, and neurodegenerative disorders (Jafri et al., [@B24]; Allen et al., [@B2]; Filippi et al., [@B13]). The longitudinal differences in FNC associated with remission from a depressed episode have yet to be investigated.

The pathophysiology of MDD can be conceptualized as a "systems-level" disorder affecting multiple brain areas and their related neurotransmitter systems (Mayberg, [@B32]; Mayberg et al., [@B33]). Functionally integrated networks or pathways in cortical and limbic regions that fail to maintain homeostatic emotional control may result in affective, cognitive, and neurovegetative symptoms of depression. In the present investigation, we focus our analysis on four regions (or components) affected in MDD: the subcallosal cingulate gyrus (SCC), default mode network, dorsal lateral prefrontal cortex, and DMPFC (Greicius et al., [@B18]; Sheline et al., [@B46]). Previous cross-sectional fMRI studies have shown increased connectivity in these networks in MDD relative to healthy comparison subjects with seed-voxel correlations (Sheline et al., [@B46]) and ICA (Greicius et al., [@B18]). Furthermore, a recent resting state fMRI investigation has shown decreased connectivity in the dorsolateral prefrontal cortex in MDD associated with ECT response (Perrin et al., [@B38]). First, we assessed differences in the longitudinal pre- and post-ECT data. Second, we compared the pre-ECT and post-ECT data with demographically matched healthy comparisons to assess the degree of normalization associated with ECT response. Third, we compared differences in FNC between ECT remitters versus non-remitters. We defined aberrant FNC as differences in the MDD group relative to the healthy comparisons subjects. We hypothesized that ECT response would be associated with normalization of aberrant FNC relationships.

Materials and Methods
=====================

Participants
------------

Prior to initiating this study, ethical approval was obtained from the Human Research Protections Office at the University of New Mexico (UNM), and the study was conducted in accordance with the principles expressed in the Declaration of Helsinki. Patients were recruited from the UNM Mental Health Center's inpatient and outpatient services. Patients had decisional capacity or assented with a surrogate decision maker providing formal consent. For this investigation, depressed patients met the following inclusion criteria: (1) DSM-IV TR diagnosis of MDD made be a board-certified geriatric psychiatrist (CA); (2) the clinical indications for ECT including treatment resistance and a need for a rapid and definitive response (Weiner et al., [@B49]); (3) a Hamilton Depression Rating Scale -- 24 item (HDRS-24) ≥ 21 (Kellner et al., [@B28]); and (4) age ≥50 years to reduce age-related heterogeneity. Exclusionary criteria included the following: (1) defined neurological or neurodegenerative disorder (e.g., head injury or epilepsy, Alzheimer's disease); (2) other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, Bipolar I or II disorder); (3) current drug or alcohol dependence; (4) contraindications to MRI (e.g., pacemaker); and (5) pregnancy.

Age- and gender-matched healthy comparison participants were recruited from the same demographic area and completed one session of resting state fMRI using the identical imaging protocol. Additional exclusion criteria for the healthy comparison group included psychiatric diagnosis and current use of psychotropic medications. The use of cross-sectional data for the comparison subjects is consistent with other longitudinal case--control studies assessing treatment effects with resting state data in neuropsychiatric disorders (Lui et al., [@B31]). Previous resting state studies have shown a high level of consistency in healthy individuals (Harrison et al., [@B22]; Shehzad et al., [@B45]; Guo et al., [@B19]).

Clinical assessments
--------------------

Patients receiving ECT underwent clinical assessments with the HDRS-24 and Hamilton Endogenomorphic Scale (HES; Thase et al., [@B47]) and cognitive assessments with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Randolph et al., [@B39]) and the Trail Making Test Parts A and B (Reitan, [@B40]) before and after the ECT series. The initial assessment occurred 1--2 days prior to ECT series, and the final imaging assessment followed the last ECT treatment by a minimum of 5 days. The delay from the last ECT treatment to the post-ECT scan minimized the subacute effects of the seizure (Schmidt et al., [@B43]). Patients were considered remitters if they had a 60% reduction in pretreatment HDRS-24 and a maximum post-treatment score of 10 following the ECT series (Sackeim et al., [@B42]).

Electroconvulsive therapy
-------------------------

The anesthetic agents included methohexital (1 mg/kg) and succinylcholine (1 mg/kg). Clinical judgment from the ECT physician determined lead placement at the start of the ECT series. A Thymatron System IV (Somatics LLC, Lake Bluff, IL, USA) delivered a right unilateral (*n* = 10) or bitemporal ECT (*n* = 2) stimulus delivery with a constant-current, brief pulse (0.50 ms). For the bitemporal stimulus delivery, the center of the stimulus electrodes were placed 3 cm above a line connecting the canthus of the eye and the external auditory meatus (Kellner et al., [@B27]). For the right unilateral stimulus delivery, the right temporal lead was placed as previously described. Another lead was placed 3 cm lateral to the right of the vertex of the skull. Seizure threshold obtained during the first session with a dose titration method guided subsequent stimulus dosage (6 × threshold for right unilateral, 2 × threshold for bitemporal; Kellner et al., [@B27]). Treatments occurred thrice weekly (Monday, Wednesday, and Friday) until adequate clinical response or clinical decision to stop treatment in the context of non-response (11.17 ± 3.33 sessions in the series).

MRI and fMRI data acquisition
-----------------------------

All MRI images were collected on the Mind Research Network (MRN) 3-Tesla Siemens Trio scanner. High-resolution T1-weighted structural images were acquired with a 5-echo MPRAGE sequence with TE = (1.64, 3.5, 5.36, 7.22, 9.08) ms, TR = 2.53 s, TI = 1.2 s, flip angle = 7, number of excitations = 1, slice thickness = 1 mm, field of view = 256 mm, resolution = 256 × 256. T2-weighted functional images were acquired with a gradient-echo EPI sequence with TE = 29 ms, TR = 2 s, flip angle = 75, slice thickness = 3.5 mm, slice gap = 1.05 mm, field of view 240 mm, matrix size = 64 × 64, voxel size = 3.75 × 3.75 × 4.55 mm. Resting state scans were acquired over a minimum of 5 min, 16 s in duration (158 volumes). Subjects were instructed to keep their eyes open during the scan and stare passively at a fixation cross.

Structural and fMRI image processing
------------------------------------

An automated pipeline and neuroinformatics system developed at the MRN and based on Statistical Parametric Mapping 5 (SPM5)[^1^](#fn1){ref-type="fn"} preprocessed the functional and structural MRI data (Scott et al., [@B44]). In the functional data pipeline, the first four volumes were discarded to remove T1 equilibration effects. Images were realigned with INRIalign (Freire et al., [@B15]), and slice-timing correction was applied with the middle slice as the reference frame. Data were then spatially normalized into the standard Montreal Neurological Institute (MNI) space, resliced to 3 mm × 3 mm × 3 mm voxels and smoothed using a Gaussian kernel with a full-width at half-maximum (FWHM) of 10 mm.

Independent component analysis
------------------------------

Group ICA (Calhoun et al., [@B7]) was performed using the Group ICA fMRI Toolbox (GIFT)[^2^](#fn2){ref-type="fn"}. In contrast to the seed-based approach, spatial ICA utilizes a data-driven multivariate approach to identify distinct groups of brain regions with temporally coherent (and hence functionally connected) hemodynamic signal change (Calhoun et al., [@B8]). The advantages of ICA over seed-based correlational techniques include the following: (1) eliminates the arbitrary choice of seed-voxel, (2) takes into account all between voxel information, (3) successfully identifies and removes motion-related sources, and (4) increases sensitivity to detect group differences (McKeown et al., [@B35]; Kochiyama et al., [@B30]; Koch et al., [@B29]; Allen et al., [@B2]).

The preprocessed fMRI data were reduced in two steps. First, subject-level data dimensionality was reduced to 100. Second, the concatenated, aggregate data was further reduced to 75. The relatively higher model order (Components, *C* = 75) identified components that correspond with known functional networks (Ystad et al., [@B51]). The Infomax algorithm was repeated 20 times with ICASSO to maximize the reliability and robustness of the component spatial maps. Subject specific time courses and spatial maps were then back reconstructed (Erhardt et al., [@B12]). Three raters (Christopher C. Abbott, Shruti Gopal, and Jessica A. Turner) used visual inspection of spatial maps and low frequency power spectra to select the components of interest (Cordes et al., [@B9]; Allen et al., [@B2]).

Functional network connectivity
-------------------------------

The FNC Toolbox (FNCtb)[^3^](#fn3){ref-type="fn"} bandpassed filtered the ICA time courses from 0.01 to 0.10 Hz and computed the differences in lagged correlations (±3 s) between pairs of the selected components (6 components, 15 pairs of correlations; Jafri et al., [@B24]). Fisher's transformation converted each correlation to a *z*-score prior to the statistical analysis.

Statistical analysis
--------------------

Because of the small sample size, we assessed normality assumptions with box plots and Levene's test for equality of variance on the demographic, clinical, and FNC Fisher transformed data. For the longitudinal differences in symptom scores (HDRS-24 and HES), we used non-parametric statistics (paired-sample Wilcoxon signed-rank test) to assess longitudinal differences before and after the ECT series.

Within ECT remitters, we assessed longitudinal differences (pre- and post-ECT) in FNC with paired *t*-tests. We used a false discovery rate (*P* \< 0.05) to correct for multiple comparisons (Genovese et al., [@B16]).

Following these analyses, we compared pre-ECT FNC measures on the significant pairs of networks to the same measures in healthy subjects using a two-sample *t*-test. We also compared post-ECT measures to the healthy subject FNC measurements in the same way. Significant threshold were set to *P* \< 0.05.

We correlated the change in FNC measures with the change in symptom measures for all subjects, and for ECT remitters only with a significance threshold of *P* \< 0.05.

Finally, a two-factor analysis of variance assessed longitudinal changes in FNC between group (ECT remitters and non-remitters) and time (pre- and post-ECT). A two-factor analysis of variance also assessed differences in stimulus delivery (bitemporal and right unilateral) and time (pre- and post-ECT).

Results
=======

Participants
------------

The average age for the depressed patients (*n* = 12) was 66.42 ± 9.78 years (four male/eight females). Eleven of the twelve depressed subjects started this study during an inpatient psychiatric hospitalization. Three subjects had a depressive episode with psychotic features and the remaining subjects had non-psychotic depressive episodes. Eleven of the twelve depressed subjects had a history of recurrent depressive episodes. All depressed subjects were treated with antidepressant medications throughout this investigation. Eight subjects were concurrently treated with antipsychotics, and two subjects were treated with a mood stabilizer (lamotrigine). Medication changes between the two imaging assessments were minimal and consisted of an antidepressant cross titration (*n* = 1), antidepressant discontinuation (*n* = 2), and the addition of an antipsychotic (olanzapine, *n* = 1). The healthy comparison subjects (*n* = 12) were matched for age and gender (age *t*~22~ = 0.90, *P* = 0.90; gender *x*^2^ = 0.00, *P* = 1.00). The demographic and clinical characteristics of the patients and comparison subjects are shown in Table [1](#T1){ref-type="table"}.

###### 

**The top section includes the demographic variables of the subjects with major depressive disorder (MDD) and demographically matched healthy comparison subjects (HC)**. The lower section includes clinical symptom ratings and neuropsychological indices (RBANS index scores, Trail Making Test Parts A and B in seconds).

  Demographics                  MDD mean (SD) or ratio   HC mean (SD) or ratio    *P*-value       
  ----------------------------- ------------------------ ------------------------ --------------- -----------------
  Age (*n* = 12)                66.42 (9.78)             67.58 (8.89)             0.83            
  Gender (M/F)                  4/8                      4/8                      1.00            
                                                                                                  
                                **Pre-ECT mean (SD)**    **Post-ECT mean (SD)**   ***P*-value**   **Cohen's *d***
                                                                                                  
  **HDRS-24**                                                                                     
  Remitters (*n* = 9)           34.56 (10.02)            2.89 (2.93)              \<0.01          4.29
  Non-remitters (*n* = 3)       33.67 (6.66)             18.33 (3.51)             0.11            2.88
  **HES**                                                                                         
  Remitters                     13.22 (2.86)             0.67 (0.71)              \<0.01          6.02
  Non-remitters                 11.00 (3.61)             5.33 (3.06)              0.11            1.69
  **RBANS (*n* = 10)**                                                                            
  Total scale                   77.10 (22.70)            80.20 (23.22)            0.43            −0.14
  Immediate memory              70.54 (25.09)            81.54 (25.48)            0.10            −0.44
  Visual spatial/construction   84.50 (24.42)            87.20 (24.56)            0.66            −0.11
  Language                      90.55 (10.33)            89.64 (17.53)            0.84            0.06
  Attention                     82.00 (25.13)            80.10 (24.32)            0.57            0.08
  Delayed memory                80.80 (23.79)            81.80 (23.39)            0.79            −0.04
  **Trails (*n* = 7)**                                                                            
  Trails A (s)                  64.14 (29.19)            50.57 (14.01)            0.11            0.59
  Trails B (s)                  181.57 (85.95)           148.00 (89.57)           0.26            0.38

*HDRS-24, Hamilton Depression Rating Scale -- 24 item; HES, Hamilton Endogenomorphy Scale; RBANS, repeatable battery for neuropsychological status*.

Clinical assessments
--------------------

Subjects completed the post-ECT assessment and imaging scan at least 5 days after their last treatment to minimize the effect of the seizure on the imaging results (mean 21.13 ± 13.90 days after the last ECT treatment). The post-ECT HDRS-24 confirmed remission from a pre-ECT assessment of 34.56 ± 10.03 to a post-ECT assessment of 2.89 ± 2.93 post-ECT for nine of the twelve subjects (*z* = 2.67, *P* = 0.0076). The ECT remitters also had a similar reduction in the HES from a pre-ECT assessment of 13.22 ± 2.86 to a post-ECT assessment of 0.67 ± 0.71 subjects (*z* = 2.67, *P* = 0.0074). The average post-ECT HDRS-24 for the non-remitter group also demonstrated a non-significant trend toward clinical improvement from a pre-ECT assessment of 33.67 ± 6.66 to a post-ECT assessment of 18.33 ± 3.51 (*z* = 1.60, *P* = 0.10) as shown in Figure [1](#F1){ref-type="fig"}. The neuropsychological indices did not show any significant differences before and after ECT (*P* \> 0.05).

![**The Hamilton Depression Rating Scale-24 (HDRS-24) is on the *y*-axis, and the pre- and post-ECT depression ratings are on the *x*-axis**. The dashed red line (HDRS-24) differentiates ECT remitters from non-remitters.](fpsyt-04-00010-g001){#F1}

Components of interest
----------------------

We refer to the individual components by functional spatial map: anterior default mode (a_DM), SCC, DMPFC, posterior default mode (p_DM), and (right/left) dorsal lateral prefrontal cortex (r_DLPFC, l_DLPFC). Figure [2](#F2){ref-type="fig"} displays the selected components of interest and Table [2](#T2){ref-type="table"} details the anatomic locations (Brodmann areas) of the selected components.

![**Maps of the networks of interest include the anterior default mode network (a_DM), subcallosal cingulate gyrus (SCC), dorsal medial prefrontal cortex (DMPFC), posterior default mode network (p_DM), and dorsal lateral prefrontal cortex (r_DLPFC, l_DPLFC)**. Each component map has a lower threshold of *t* = 10. The images are shown in radiological convention. The arrows represent the significant (FDR-corrected), longitudinal differences in FNC associated with ECT response.](fpsyt-04-00010-g002){#F2}

###### 

**Networks of interest**.

  Area                                                   Brodmann areas          R/L (cm^3^)   R/L (max-*t*, MNI coordinates)
  ------------------------------------------------------ ----------------------- ------------- ----------------------------------------
  **ANTERIOR DEFAULT MODE (a_DM)**                                                             
  Anterior cingulate                                     10, 24, 32              6.3/6.8       27.3 (−3, 47, 9)/24.2 (3, 44, 12)
  Superior frontal gyrus                                 9, 10                   6.8/5.9       24.6 (−3, 54, 28)/18.4 (18, 51, 22)
  Middle frontal gyrus                                   10                      0.5/0.7       14.6 (−24, 51, 20)/15.9 (24, 53, 19)
  Cingulate gyrus                                        32                      0.2/0.2       13.6 (−3, 36, 26)/14.5 (3, 36, 26)
  Subcallosal gyrus                                      25                      0.0/0.1       (\_, \_, \_)/12.2 (3, 23, −11)
  **SUBCALLOSAL CINGULATE GYRUS (SCC)**                                                        
  Caudate                                                                        1.3/1.2       31.4 (−6, 14, −3)/27.4 (6, 11, −3)
  Anterior cingulate                                     10, 24, 25, 32          3.4/3.8       26.8 (−3, 11, −3)/25.3 (3, 14, −6)
  Medial frontal gyrus                                   10, 11                  0.6/0.8       17.0 (−9, 26, −11)/23.0 (6, 26, −11)
  Subcallosal gyrus                                      11, 13, 25, 47          1.2/1.0       21.0 (−3, 14, −11)/21.6 (3, 20, −11)
  Lentiform nucleus                                                              0.4/0.2       14.1 (−12, 6, −5)/14.1 (12, 6, −3)
  Inferior frontal gyrus                                 47                      0.1/0.2       10.3 (−21, 14, −16)/12.7 (21, 17, −16)
  Parahippocampal gyrus                                                          0.1/0.0       10.1 (−12, −7, −15)/(\_, \_, \_)
  **DORSAL MEDIAL PREFRONTAL CORTEX (DMPFC)**                                                  
  Cingulate gyrus                                        24, 32                  6.0/6.5       22.1 (−3, 11, 38)/26.0 (6, 22, 32)
  Medial frontal gyrus                                   6, 8, 9, 32             4.1/3.2       20.8 (−3, 23, 43)/21.8 (3, 25, 40)
  Middle frontal gyrus                                   9                       0.3/1.0       11.9 (−30, 33, 29)/21.7 (30, 36, 29)
  Anterior cingulate                                     24, 32, 33              2.0/1.9       15.5 (−3, 10, 24)/16.3 (3, 16, 24)
  Superior frontal gyrus                                 6, 8, 9                 1.3/1.4       14.3 (−3, 34, 43)/14.7 (33, 37, 31)
  Paracentral lobule                                     5, 31                   0.1/0.2       10.5 (0, −24, 43)/11.0 (3, −21, 43)
  Postcentral gyrus                                      5                       0.0/0.1       (\_, \_, \_)/10.8 (6, −40, 66)
  Insula                                                 13                      0.1/0.0       10.1 (−33, 14, −3)/(\_, \_, \_)
  **POSTERIOR DEFAULT MODE (p_DM)**                                                            
  Precuneus                                              7, 23, 31               14.3/12.2     29.8 (−3, −57, 30)/28.0 (3, −57, 30)
  Cingulate gyrus                                        23, 31                  5.7/3.5       29.2 (−6, −57, 28)/25.5 (6, −54, 28)
  Cuneus                                                 7                       0.4/0.3       27.9 (−6, −65, 31)/20.8 (6, −65, 31)
  Posterior cingulate                                    23, 29, 30, 31          4.4/3.4       25.7 (−6, −54, 25)/26.3 (9, −54, 25)
  **RIGHT DORSAL LATERAL PREFRONTAL CORTEX (r_DLPFC)**                                         
  Inferior frontal gyrus                                 9, 13, 44, 45, 46, 47   16.5/4.4      27.9 (−50, 27, 18)/18.0 (48, 21, 7)
  Middle frontal gyrus                                   9, 10, 46, 47           5.8/0.1       24.3 (−48, 27, 21)/10.9 (48, 33, 15)
  Insula                                                 13                      4.9/0.2       22.9 (−45, 12, 2)/10.9 (39, 15, 10)
  Precentral gyrus                                       6, 44                   3.1/0.3       22.4 (−50, 9, 13)/18.1 (50, 18, 7)
  Superior temporal gyrus                                22                      0.8/0.0       17.0 (−45, 11, −3)/(\_, \_, \_)
  Inferior temporal gyrus                                                        0.1/0.0       10.1 (−50, −59, −7)/(\_, \_, \_)
  **LEFT DORSAL LATERAL PREFRONTAL CORTEX (l_DLPFC)**                                          
  Inferior frontal gyrus                                 6, 9, 44, 45, 46        3.9/8.1       18.0 (−48, 10, 27)/30.6 (48, 21, 21)
  Middle frontal gyrus                                   6, 8, 9, 46             6.8/16.1      18.3 (−45, 13, 27)/26.5 (50, 16, 27)
  Precentral gyrus                                       6, 9                    0.4/2.9       12.5 (−45, 19, 35)/18.3 (42, 16, 35)
  Superior frontal gyrus                                 8, 9                    0.0/0.4       (\_, \_, \_)/11.4 (33, 11, 52)
  Inferior parietal lobule                               40                      0.0/0.1       (\_, \_, \_)/10.4 (53, −46, 22)
  Postcentral gyrus                                                              0.0/0.1       (\_, \_, \_)/10.2 (45, −10, 25)

*We applied a one-sample *t*-test to determine the areas of strongest weighting within each ICA spatial map. The anatomic areas described here are the same areas in Figure [2](#F2){ref-type="fig"} (each component map has a lower threshold of *t* = 10.)*.

Functional network connectivity
-------------------------------

Our primary analysis assessed pre- and post-ECT longitudinal changes in FNC among ECT remitters (*n* = 9). Among 15 component correlations, two pairs of components had significant FNC changes associated with ECT response (*P*~FDR~ \< 0.05). The FNC measures between p_DM and the DMPFC increased from a negative (*r* = −0.49) to a positive correlation (*r* = 0.36) during the ECT series (*t*~8~ = −5.38, *P* \< 0.001). The FNC measures between the p_DM and the l_DLPFC correlation also increased from negative (*r* = −0.50) to a weak positive correlation (*r* = 0.010) during the ECT series (*t*~8~ = −3.85, *P* = 0.0049). These longitudinal, between network changes are shown in Figure [3](#F3){ref-type="fig"} and reported in Table [3](#T3){ref-type="table"}.

![**(A)** Functional network connectivity (FNC) increased between the p_DM and DMPFC pre- to post-ECT. FNC correlations are represented on the *y*-axis. The red lines (dashes) are the means (standard errors) of the matched healthy comparison FNC correlations. Relative to healthy comparisons, the pre-ECT FNC was significantly reduced and normalized with ECT response. **(B)** The p_DM and l_DLPFC had a similar increase in FNC associated with the ECT series. (DMPFC, dorsal medial prefrontal cortex; p_DM, posterior default mode network; l_DLPFC, left dorsal lateral prefrontal cortex.)](fpsyt-04-00010-g003){#F3}

###### 

**Functional network connectivity (FNC) results are shown for the paired- and two-sample *t*-tests**.

  Component pair    Pre/post *t*~8~ (*P*)                           Pre/HC *t*~16~ (*P*)   Post/HC *t*~16~ (*P*)
  ----------------- ----------------------------------------------- ---------------------- -----------------------
  a_DM/SCC          0.94 (0.38)                                                            
  a_DM/DMPFC        1.38 (0.20)                                                            
  a_DM/p_DM         −1.95 (0.09)                                                           
  a_DM/r_DLPFC      1.01 (0.34)                                                            
  a_DM/l_DLPFC      1.73 (0.12)                                                            
  SCC/DMPFC         1.28 (0.24)                                                            
  SCC/p_DM          −0.15 (0.89)                                                           
  SCC/r_DLPFC       1.27 (0.24)                                                            
  SCC/l_DLPFC       2.62 (0.03)                                                            
  DMPFC/p_DM        −4.66 (0.002)[\*](#tfn1){ref-type="table-fn"}   −3.22 (0.005)          0.82 (0.42)
  DMPFC/r_DLPFC     0.17 (0.87)                                                            
  DMPFC/l_DLPFC     0.09 (0.93)                                                            
  p_DM/r_DLPFC      −1.91 (0.09)                                                           
  p_DM/l_DLPFC      −3.85 (0.005)[\*](#tfn1){ref-type="table-fn"}   −3.23 (0.005)          0.11 (0.91)
  r_DLPFC/l_DLPFC   0.48 (0.07)                                                            

*The paired *t*-tests between the pre- and post-ECT data within ECT remitters are presented in the second column. *Post hoc* two-sample *t*-tests (third and fourth columns) for the significant pre- and post-ECT component pairs were conducted between the ECT subjects and the healthy comparisons (HC)*.

*\*False discovery rate significant at *P* \< 0.05*.

*a_DM, anterior default mode; p_DM, posterior default mode; r_DLPFC, right dorsal lateral prefrontal cortex; l_DLPFC, left dorsal lateral prefrontal cortex; DMPFC, dorsal medial prefrontal cortex; SCC, subcallosal cingulate*.

The secondary analyses focused on the two network pairs that demonstrated significant longitudinal differences after the ECT series. Relative to the healthy subjects, the pre-ECT subjects had significantly lower FNC measures between p_DM and DMPFC (*t*~16~ = −3.22, *P* = 0.005) and the pDMN and l_DLPFC (*t*~16~ = −3.23, *P* = 0.005). The post-ECT and healthy comparison contrasts for both network pairs were not significant (*P* \> 0.05). Pairwise correlations between changes in FNC and symptom changes were not significant, whether performed over all 12 ECT subjects or the 9 remitters only (*P* \> 0.05).

The two-factor ANOVA comparing groups (ECT remitters and non-remitters) and time (pre- and post-ECT) had significant group × time interactions for p_DM and l_DLPFC (*f*~1,\ 20~ = 7.52, *P* = 0.013). The FNC measures increased from pre- to post-ECT for the remitters but not for the non-remitters. The interaction was not present with for p_DM and DMPFC (*P* \> 0.05). The two-factor ANOVA comparing stimulus delivery (bitemporal and right unilateral) and time (pre- and pot-ECT) was not significant for the stimulus delivery × time interaction for both FNC correlations (*P* \> 0.05).

Discussion
==========

This investigation assessed changes in FNC associated with ECT response in MDD. ECT response reverses the relationship from negative to positive between two pairs of networks: the p_DM/DMPFC and the p_DM/l_DLPFC. Relative to healthy comparisons, both of the aberrant network pairs (i.e., different pre-ECT relative to HC) normalized with ECT response. Although the change in FNC did not predict symptom improvement, the correlation between the p_DM/l_DLPFC did not increase in the ECT non-remitters. The differences between ECT remitters and non-remitters suggest that changes in FNC are related to the therapeutic underpinnings of ECT, as opposed to epiphenomenon.

In order to contextualize our findings with Perrin et al.'s longitudinal resting state fMRI ECT investigation, we compare FNC with seed-voxel correlations. Sheline et al.'s ([@B46]) "hyperconnectivity" hypothesis posits that treatment response during a depressed episode may be associated with reduced seed-voxel functional connectivity, which is supported by the Perrin et al. ([@B38]). Perrin et al.'s ([@B38]) investigation demonstrated reduced functional connectivity with seed-voxel correlations in the l_DLPFC. Their analysis, as they point out, did not indicate a change in connectivity between the DLPFC and specific other regions, but that the overall connectivity from the DLPFC to the rest of the brain was changed with ECT treatment. Seed-voxel correlations are the summation of ICA-derived within network connectivities (power) and ICA-derived between network connectivities (FNC; Joel et al., [@B25]). Thus, FNC is a part of the seed-voxel functional connectivity totality. Our results, which show increased temporal coherence between anterior and posterior independent components with ECT response (i.e., increased FNC) offer more specificity regarding type and direction change between components associated with recovery from a depressed episode.

Similar to Perrin's investigation, ECT response was specific for the l_DLPFC despite the different analysis methods. Previous cross-sectional investigations have established the relationship between depression severity and cognitive deficits with aberrant connectivity between the dorsal lateral prefrontal and default mode regions (Vasic et al., [@B48]; Goveas et al., [@B17]). Executive function, largely dependent on intact prefrontal and frontal lobe performance, has emerged as one of the core cognitive deficits in major depression and may be related to deficits in attentional control and maladaptive ruminative thought (Austin et al., [@B3]).

Electroconvulsive therapy response was associated with increased FNC (or loss of anticorrelation) between the dorsal lateral prefrontal cortex and the default mode. We offer two potential explanations regarding the loss of the well-established anticorrelation between these two regions (Fox et al., [@B14]). First, our sample is older and age-related changes, which show diminished anticorrelations between these networks, may provide the context for interpreting the direction of change from negative to weakly positive (Wu et al., [@B50]). Second, dynamic FNC changes, as opposed to the implicit assumption of "stationarity" (i.e., the relationship between components does not change during the fMRI run), may also explain the increased FNC correlations (Allen et al., [@B1]). In healthy participants, the default mode and dorsal attentional systems have been established as "zones of instability" characterized by functional connections that "emerge and dissolve" (Allen et al., [@B1]). Although not tested in this investigation, ECT response may normalize dynamic FNC among the zones of instability resulting in the return of the ebb and flow of negative and positive relationships between these networks.

Electroconvulsive therapy response may have anatomic specificity with respect to FNC differences. The p_DM network, which has been implicated in depression conceivably through its role in maladaptive, depressive ruminations (Hamilton et al., [@B21]), is involved in both of the between network changes and appears to be a FNC "hub" for network changes in the context of ECT response. In contrast, the SCC, which has been the target of therapeutic interventions from antidepressant medications to deep brain stimulation, is not involved with any between network changes tested in this investigation, despite being extensively implicated in the pathophysiology of MDD. Normally, therapeutic interventions in this area are associated with reduced activity (Hamani et al., [@B20]). In the absence of between network changes, our data suggests that the SCC may be more impacted by within network changes in the context of ECT response. Larger investigations are needed to confirm these findings.

Some limitations of this investigation should be acknowledged. First, the small sample size limited further analyses between clinical and treatment variables (e.g., psychotic versus non-psychotic depression). Second, MDD subjects were medicated at both assessment points, confounding a straightforward interpretation of ECT effects. Because of the acuity of the depressed episodes, withdrawing medications would not have been feasible prior to the first imaging assessment, and the expert consensus is that antidepressant medications act synergistically with ECT to enhance response (Weiner et al., [@B49]; Sackeim et al., [@B41]). However, only 3 of the 12 subjects had modification in their antidepressant drug therapy during the ECT course, reducing the likelihood of a confounding effect of the medications. However, antidepressant medications may also reduce functional connectivity (McCabe and Mishor, [@B34]). As previously discussed, FNC is a part of the seed-voxel functional connectivity totality (Joel et al., [@B25]) and FNC is also measuring functional connectivity (Joel et al., [@B25]). We hope to study these effects in future work with more extensive numbers of subjects on different medication levels.

In conclusion, this research enhances our understanding of the functional neural correlates of ECT response. Continued research in this area may differentiate ECT remitters from non-remitters prior to the ECT series and identify patients at risk of relapse immediately following the ECT series, an essential step in the development of biomarkers for treatment response in MDD. Results from this study may also be applicable to a spectrum of treatments for MDD of varying invasivity. For example, many focal neuromodulation treatments have excellent safety profiles, such as transcranial magnetic stimulation or transcranial direct-current stimulation, which do not require anesthesia and have the potential for widespread use beyond academic medical centers and large, metropolitan hospitals (Pascual-Leone et al., [@B37]). Despite this safety profile, the speed of response and efficacy of other neural modulation treatments does not match the "gold-standard" of ECT (Eranti et al., [@B10]; Kalu et al., [@B26]). A better understanding of ECT response may improve the efficacy of potentially safer, more accessible treatments for MDD.
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